Creo Medical (LSE:CREO) represents the medical technology end of the FTSE AIM All Share Index, developing advanced energy-based devices for minimally invasive surgical endoscopy.

What the company does

Creo Medical, which is based in Wales, develops surgical devices that combine bipolar radiofrequency energy for cutting with microwave energy for coagulation. Its technology platform, delivered through a dedicated electrosurgical generator, is designed to power a range of flexible instruments that can be passed through an endoscope. The aim is to allow clinicians to carry out procedures that might otherwise require more invasive surgery, potentially reducing recovery times and costs for healthcare systems.

The company's product family has included the Speedboat device, used in gastrointestinal procedures such as the removal of early-stage lesions, as well as other instruments for applications in areas including the lung and pancreas. Creo has invested heavily in clinician training and education programmes, since adoption of advanced endoscopic techniques depends on building a community of skilled users. The group has also worked with partners and distributors to widen access to its technology in international markets.

Latest developments

For a company of this kind, regulatory clearances and evidence from clinical use can be important milestones.

Financial and dividend picture

Creo Medical has been in a period of investment and commercial build-out, and like many medical technology developers at this stage it has reported losses while spending on product development, regulatory work and market development. The company has relied on share fundraisings and other transactions to finance its plans and does not have a record of paying dividends. Management attention to cash runway is therefore a key theme.

Sector and index context

Within the FTSE AIM All Share Index, Creo sits within the healthcare sector alongside a varied group of medical device, diagnostics and life sciences companies. AIM has long served as a provider of growth capital for UK medtech businesses, although sentiment towards early commercial-stage companies can be volatile. Demand for minimally invasive procedures is supported by healthcare systems' efforts to reduce hospital stays and manage costs, while competition comes from large global medical device companies with extensive sales networks and established product ranges.

Key risks

Key risks include the pace of clinical adoption, which depends on training, evidence and reimbursement, and the need to secure regulatory approvals in different markets. As a loss-making company, Creo may need further funding, which could dilute shareholders. Competition from larger players, manufacturing and supply chain challenges, and the reliance on partners in some territories add further uncertainty. Share price volatility can be significant for companies at this stage of development.

What to watch next

Investors will likely watch for growth in procedure numbers and device sales, progress with new product approvals, publication of clinical data and updates on partnerships. The company's cash position, cost discipline and path towards profitability will be closely followed. Results and trading updates should show whether commercial momentum is building in its key markets and whether the business is moving closer to self-funding.